ORIGINAL ARTICLE

Inhibition of activated NR2B gene‑ and caspase‑3 protein‑expression by glutathione following traumatic brain injury in a rat model

Muhammad Zafrullah Arifinⁱ, Ahmad Faried^{ı,2}, Muhammad Nurhalim Shahib³, Kahdar Wiriadisastra', Tatang Bisri⁴

¹Department of Neurosurgery, ²Stem Cell Working Group, and ³Departments of Biochemistry, ⁴Anesthesiology, Faculty of Medicine, Universitas Padjadjaran–Dr. Hasan Sadikin Hospital, Bandung, Indonesia

ABSTRACT

Background. Traumatic brain injury (TBI) remains a major cause of death and disability. Oxidative stress is an important element of the injury cascade following TBI. Progressive compromise of antioxidant defenses and free radical-mediated lipid peroxidation are one of the major mechanisms of secondary TBI. *NR2B* is a glutamate receptor and its activation is caused by TBI increasing a brain cell death, along with caspase-3 as a hall mark of apoptosis. Glutathione is a potent free radical scavenger that might prevent secondary TBI damage and inhibited apoptosis.

Materials and Methods. In the present study, it aims to demonstrate the effect of glutathione on inhibition of brain oxidative damage in a TBI rat model.

Results. In this study, the expressions of mRNA *NR2B* in placebo group and groups with glutathione administration at 0, 3, and 6 hours after TBI were 328.14, 229.90, 178.50, and 136.14, respectively (*P*<0.001). The highest caspase-3 expression was shown in placebo group with 66.7% showing strong positive results (>80%); as expected, glutathione administered in 0, 3, and 6 hours groups had lower strong positive results of 50%, 16.7%, and 16.7%, respectively, (*P*=0.025).

Conclusion. In conclusion, this study showed that glutathione administration in a TBI rat model decreased *NR2B* geneand caspase-3 protein-expression that lead to the inhibition of brain cell death. Our results suggest that glutathione, as a potent free radical scavenger, has a brain cell protective effect against oxidative damage and cell death induced by TBI in rat model.

Key words: Caspase-3, glutathione, *NR2B* gene, traumatic brain injury

Introduction

Traumatic brain injury (TBI) remains a major cause of death and disability with an estimated annual occurrence of 1.4 million cases in the United States.[1] In Panti Nugroho Pakem Hospital, Yogyakarta, Indonesia, TBI cases were reported in the first quarter of year 2005, which ranked fifth

Address for correspondence:

Dr. Ahmad Faried, Department of Neurosurgery, Faculty of Medicine, Universitas Padjadjaran–Dr. Hasan Sadikin Hospital, Jl Pasteur 38, Bandung 40161, Indonesia. E‑mail: faried.fkup@gmail.com

of all visits to the emergency room and the second of all causes of hospitalization; of those cases, 17.8% was referred to the main-hospital with a mortality rate of 2.7%.^[2] The Department of Neurosurgery at Dr. Hasan Sadikin Hospital (RSHS), Bandung, Indonesia, received 1212 cases within the 11 months of 2000 or more than 100 cases/month. The incidence was increased by 11.6% (1352) in 2006. In August 2007, 258 out of 462 accident cases were TBI (44.2%).[3]

TBI can be classified as primary, which occurs immediately following a trauma and continues to evolve during the subsequent hours and days after the initial insult in what is referred to as a secondary injury.^[4] Improved outcomes might be achieved by preventing or reducing the secondary injury. Limiting a secondary injury results in lower mortality rates, improved functional outcome scores, shorter hospital stay, and decreased charges.[5,6]

Several pathogenetic mechanisms of secondary damage, including derangements in cerebral blood flow, excitotoxicity,

reactive oxygen species (ROS), inflammation, and apoptosis have been described.^[7] Two signaling pathways for the initiation of apoptosis are well known: One is mediated by a dead receptor, which is called an "extrinsic pathway," and the other, the "intrinsic pathway," is mediated by mitochondria.[8,9] In both pathways, the induction of apoptosis leads to the activation of initiator caspases: Caspase‑8 for the extrinsic pathway, and caspase‑9, which is activated at the apoptosome for the intrinsic pathway, which finally activates caspase's executor, caspase-3.[10]

The *N*-methyl-D-aspartate (NMDA) receptor is a heteromeric ligand gated ion channel that interacts with multiple proteins.[11,12] NMDA receptors are composed of association of subunits that belong to two families: A single gene product (*NR1*) with eight splice variants and four different *NR2* subunits (*NR2A*, *B*, *C*, *D*) produced by a different gene.[13] Within the brain, the *NR1*, *NR2A* and *NR2B* subunits are more prominent in cortical areas and the hippocampus than in white matter and cerebellum.[14] On the other hand, the *NR2B* subunits are expressed at the highest levels in the hippocampus, cerebral cortex, and olfactory bulb.[15] Recently, Liu *et al*., reported that activation of *NR2B*‑ containing NMDA receptor results in excitotoxicity and increasing neuronal apoptosis.^[16] These events are very important to promote a brain cell protection.

The exposure of oxidative stress such as free radicals has been suggested as a major cause of neural cell death following TBI.[17,18] The brain's antioxidant mechanisms include superoxide dismutase (SOD) which converts free radicals to hydrogen peroxide (H $_{\rm 2}$ O $_{\rm 2}$), and glutathione peroxidase which further metabolized $\rm{H}_{2}O_{2}$ to $\rm{H}_{2}O$ and $\rm{O}_{2}.^{\rm{[19]}}$ Oxidative stress is harmful due to its high fatty acid content and proportionately large share of total body oxygen consumption.^[20] SOD over expression has a protective effect against ischemic injury.[21,22] Endogenous glutathione is up regulated in the brain in response to TBI to compensate the damage.[23] We speculated that exogenous glutathione would be needed to prevent a secondary TBI damage and inhibit apoptosis.

The aim of the present study was to examine the effect of glutathione administration on the expressions of mRNA *NR2B* and caspase‑3 as indicators of early apoptosis‑sign after a brain injury on a TBI rat model. We hypothesized that glutathione administered shortly after brain injury has a protective effect against the long‑term sequelae of TBI by inhibiting the expression of *NR2B* and caspase-3.

Materials and Methods

Animal studies

Specific pathogen-free adult male Wistar rats were obtained from Bandung Institute of Technology with standard of Animal Care Committee, Bandung, Indonesia. They were maintained on a standard laboratory feed in a 12‑hour (h) light/dark cycle. This study was approved by the Animal Research Ethics Board of Universitas Padjadjaran, Bandung, Indonesia. After a one‑week period of environmental adaptation, the rats (*n*=30) weighing~400 gm were divided into five groups: (A) Control: Without TBI and without treatment, (B) Placebo: With TBI and administration of NaCl 0.9% soon after TBI, (C) Glutathione 0 h: With TBI, administration of glutathione 10.8 mg soon after TBI, (D) Glutathione 3 h: TBI, administration of glutathione 10.8 mg 3 h after TBI, and (E) Glutathione 6 h: With TBI, glutathione 10.8 mg 6 h after TBI and euthanized 3 h later (*n*=6). Some parts of the brain were stored in RNA‑later for subsequent RNA isolation and other parts of the brains were fixed in 10% formalin, 4 μm sections and processed for tissue staining.

Traumatic brain injury rat model

Male rats were anesthetized with pentotal intraperitoneally 40 mg/kg body weight. After a midline skin incision, a 5‑7 mm craniotomy was made from 3 mm right posterior of the bregma and 2 mm right lateral to the midline. The animals were then subjected to TBI using a small iron bar, receiving a contact velocity of 571.17 Newton/ $mm²$. The contact velocity is equal to a mild TBI.^[24] After the injury, the craniotomy was closed and the rats were returned to their cages.

Drug (Glutathione) administration

A total of 10.8 mg (0.018×600 mg) of glutathione **(**Tationil® 600 mg/4 ml from Roche, Italy) was injected intraperitoneally. For rats weighing~400 grams, this equals to 600 mg of glutathione for human (70 kg).

RNA isolation and cDNA synthesis

Total RNA was extracted from fresh brain tissue using an RNeasy Mini kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. The quantity of isolated RNA was measured using an ND‑1000 Spectrophotometer (NanoDrop Tech Inc., Rockland DE). Template cDNA was synthesized from 13.5 μg of total RNA with an Omniscript Reverse Transcriptase kit (Qiagen, Hilden, Germany), Random Primer (hexadeoxyribonucleotide mixture, Takara, Shiga, Japan) and Ribonuclease Inhibitor (Porcine liver, Takara, Japan). Total RNA was reverse-transcribed with four units of Omniscript Reverse Transcriptase in a reaction volume of 20 μl (60 min at 37°C, 5 min at 93°C, and finally put on ice). The cDNA samples were stored at −30°C until analysis.

Reverse transcription‑polymerase chain reaction Reverse transcription-polymerase chain reaction (RT-PCR) was performed with a one step system (Promega BioSci., San Luis, CA, USA) using *NR2B* primers described previously;[25] forward: GGTAGCCATGAACGAGACTG and reverse: TTCACGAAGTCCTGGTAGCC. RT‑PCR mix were subjected to RT for 45 min at 45 \degree C, followed by inactivation of RT enzyme at 94 \degree C (2 min) and PCR (40 cycles) consisted of 94 \degree C (30 sec), 60 \degree C (1 min), and 68 \degree C (2 min) with final extension at 68 \degree C (10 min). The products were then run on a 3% agarose gel. Densitometry was performed by using Adobe Photoshop

(Apple Inc., Cupertino, CA, USA) acquisition and analysis by the Quantity One (BioRad Inc., Melville, NY, USA).

Immunohistochemistry for caspase‑3

Immunohistochemical staining of anti-caspase-3 antibody was performed by streptoavidin‑biotin as described previously.[26] Sections of four μm thick were deparaffinized and incubated with fresh 0.3% hydrogen peroxide in methanol for 30 min at room temperature. The specimens were then incubated with anti-caspase-3 antibody (Biocare Medical, Concord, CA, USA) as the primer antibody at a 1:100 dilution. The specimens were counterstained with H and E. Negative controls were prepared by substituting normal mouse serum for each primary antibody: No detectable staining was evident. The degree of staining was scored as we previously described.^[26] The sections were evaluated by two investigators without the knowledge of the pathological background.

Statistical analysis

Statistical analysis was performed using the Stat View software (ver. 5.0, SAS Institute Inc., NC, USA). The differences were considered statistically significant when *P* value was <0.05 (ANOVA).

Results

We examined the effects of glutathione treatment on a TBI rat model at the molecular level. Isolated RNA from the rats' brains' was then subjected to RT‑PCR to observe *NR2B* gene at 341 base-pair (bp). *NR2B*, as shown in [Figures 1 and 2], was observed slightly in control brains (Group A, 96.25±20). In contrast, strong expressions were observed in placebo group (Group B, 328.14 \pm 24), as shown in [Figure 3], and gradually decreased in three other treated groups (Group C, 229.9±41; Group D, 178.5 \pm 41; and Group E, 136.14 \pm 63), as shown in [Figures 2 and 3]. The results showed that *NR2B* gene expression gradually decrease from placebo group to glutathione treated groups (*P*<0.001; [Figure 3]) in a time‑dependent manner, it might be due to neurotoxicity-decreased (represented by decreased *NR2B* as glutamate receptors) effect which lead to the inhibition of brain cell death. Our results suggested that glutathione as a potent antioxidant had a brain cell protection in TBI.

Furthermore, we observed caspase-3 expression in the cytoplasm of brain cells [Figures 4 and 5]. Expression of caspase‑3 was not observed in control brains (Group A). By comparison, strong expression of caspase‑3 was observed in placebo group (Group B, 66.7% was strong positive >80%), as shown in [Figure 4] and gradually decreased in three other treated groups (Group C, 50% was strong positive >80%; Group D, 16.7%; and Group E, 16.7%) as shown in [Figure 5]. The results showed that caspase-3 protein expressions gradually decrease from placebo group to glutathione treated groups (*P*=0.025; Table 1). The expressions of caspase‑3 on a TBI rat model treated with glutathione were significantly lower than the expressions observed among those in the placebo group; the presence of this antigen was found to be strongly associated with glutathione treatment ($P=0.025$; Table 1). Glutathione administered shortly after brain injury as a single dose of 10.8 mg prevented the increase in cell death (represented by decreased caspase‑3 as hall mark of apoptosis) in traumatized brain hemispheres.

Table 1: Distribution of caspase-3 protein expression in TBI rat model treated with Glutathione

* Chi-square test; TBI - Traumatic brain injury

Figure 1: RT‑PCR results of the *NR2B* gene expression. PCR products identified following RT‑PCR of *NR2B* gene expression. The presence of 341 base pair (bp) fragment represents expression of *NR2B* in group A and group B (a)

Asian Journal of Neurosurgery ⁷⁴ Vol. 6, Issue 2, July-December 2011

Arifin, *et al*.: Glutathione inhibited *NR2B* gene‑ and caspase‑3-expression after traumatic brain injury

Figure 2: Expression of *NR2B* in group B, C, D and E, respectively (b)

Figure 3: Densitometric estimation of *NR2B* in each group (c). For group‑explanation see Materials and Methods. Line 1: DNA ladder marker 100 bp. Lanes 2‑6: Six rats brain tissue in each group

Discussion

Our study demonstrated a temporal sequence of event following TBI, which included a mark increase of *NR2B* and caspase‑3 expression levels in placebo group of TBI rat model, indicating that peroxidation of lipid membrane as well as oxidative stress produced by head trauma induced damage of Deoxyribonucleic acid (DNA) and proteins.^[27] The oxidative stress played a key role in mediating secondary brain injury induced cell death by TBI.^[24,28] When the tissues are exposed to oxidative stress, they increase the activity and expression of antioxidant enzymes as a compensatory mechanism against free radical-mediated damage. Nevertheless, the increased activity of the antioxidant enzymes may be inadequate to counteract the potential damage in many conditions of oxidative stress.[29] Moreover, antioxidant enzyme activities have been found to be diminished under highly elevated oxidative stress conditions as a result of molecular damage. On the other hand, over expression of the glutathione enzyme as one of the antioxidant and anti peroxidase which strongly decrease the cell death from brain injury.[30]

The brain is particularly vulnerable to oxidative injury because of its high rate of oxygen consumption and intense production of reactive radicals. NMDA receptor (NMDAR), a glutamate receptor, mediates neural plasticity and synaptic transmission in the mammalian central nerves system and also neuronal cell death.[31,32] Recently, *NR2B* receptor was shown to have different roles in supporting neuron survival and mediating neuronal cell death and hence had the impacts on neurotoxicity of brain.^[16] Liu *et al*., reported that the activation of *NR2B*‑containing NMDA receptor resulted in excitatoxicity and an increasing neuronal apoptosis.[16] Shahib *et al*., showed that the increase of *NR2B* expression is needed at certain level otherwise it might induce apoptosis.[25]

Figure 4: Immunohistochemistry results of the caspase‑3 protein expression. The brown color represents a positive staining of caspase‑3. Expression of caspase‑3 in group A and group B (a)

Figure 5: Expression of caspase-3 in each group B, C, D and E, respectively (b). For group-explanation see Materials and Methods

Nerve cell damage that is caused by the rupture of brain blood vessels is the result of excessive release of glutamate from nerve cells and glial (marked by increased of the *NR2B* expression) and not because of hypoxic or ischemic mechanism.[33] Glutamate then activates at least three types of NMDA receptor (*NR2B*, Kainate, and AMPA). These receptos could increase intracellular Ca^{2+} level.^[34] Since NMDA is paired with Ca^{2+} channel, activation of both will be followed by an influx of Ca^{2+} , sodium, water, and chloride into the intracellular‑space causing cellular swelling or cytotoxic-edema.[35,36] The increasing level of intracellular Ca+ will increase ${\rm H}_{\rm _2}{\rm O}_{\rm _2}$ (peroxide) as well. The above events will produce nitric oxide, ROS, cofactor caspases from mitochondria that activate caspase‑3 as the executor caspase and eventually cause cell death.[37,38] The excessive release of glutamate induced exitatory which effect leads to a decrease in endogenous glutathione. Additional exogenous glutathione which acts as an antioxidant and anti peroxide will slow brain cell death process and prevent further damage in viable brain cells.

Conclusion

In conclusion, this study showed that glutathione administered as a single dose of 10.8 mg prevents the brain oxidative damage induced by TBI in the rats by inhibiting the expression of *NR2B* and caspase‑3 expression. Our results suggest that glutathione must be administered shortly after brain injury since the therapeutic time window in brain injury is very narrow (between 3 to 6 hours). The outcome of this study is expected to encourage the progress of traumatic brain injury studies in Indonesia. Further studies will be needed to elucidate the adjuvant glutathione therapy mechanism in the clinical setup of TBI.

Acknowledgment

We thank Prof. Dr. med. Tri Hanggono Achmad and Prof. R. M. Padmo Santjojo for their expertise and fruitful discussion. This work has been partly supported by Universitas Padjadjaran's research grant-in-aids for Ahmad Faried.

References

- 1. Centers for Disease Control and Prevention, National Center for Injury Prevention and Control. Traumatic Brain Injury. 2006. Available from: http://www.cdc.gov/ncipc/tbi/TBI.htm. [Last cited on 2011 Jun 12].
- 2. Wijanarka A, Dwiphrahasto I. Implementation of clinical governance: Indicator development of head injury clinic in emergency unit. J Health Serv Manage 2005;8:213‑20.
- 3. Arifin MZ. Glutathione effect on glutamate receptor and cell death after traumatic brain injury. Doctorate Dissertation, Department of Neurosurgery, Bandung, Indonesia: Universitas Padjadjaran; 2010.
- 4. Fakhry SM, Trask AL, Waller MA, Watts DD. Management of brain injured patients by an evidence-based medicine protocol improves outcomes and decreases hospital charges. J Trauma 2004;56:492‑500.
- 5. Palmer S, Bader MK, Qureshi A, Palmer J, Shaver T, Borzatta M, *et al*. The impact on outcomes in a community hospital setting of using AANS Traumatic Brain Injury Guidelines. J Trauma 2001;50:657‑64.
- 6. Stein SC, Spettell CM. Delayed and progressive brain injury in children and adolescents with head trauma. Pediatr Neurosurg 1995;23:299-304.
- 7. Gupta S. Molecularsteps of death receptor and mitochondrial pathways of apoptosis. Life Sci 2001;69:2957‑64.
- 8. Krammer PH. CD95 (APO-1/Fas)-mediated apoptosis: Live and let die. Adv Immunol 1999;71:163‑210.
- 9. Schmitz I, Kirchhoff S, Krammer PH. Regulation of death receptormediated apoptosis pathways. Int J Biochem Cell Biol 2000;32:1123‑36.
- 10. Igney FH, Krammer PH. Death and anti-death: Tumour resistance to apoptosis. Nat Rev Cancer 2002:2:277‑88.
- 11. McBain CJ, Mayer ML. *N*‑methyl‑D‑aspartic acid receptor structure and function. Physiol Rev 1994;74:723‑60.
- 12. Mutel V, Buchy D, Klingelschmidt A, Messer J, Bleuel Z, Kemp JA, *et al*. *In vitro* binding properties in rat brain of [3H]Ro25‑6981, a potent and selective antagonist of NMDA receptors containing NR2B subunits. J Neurochem 1998;70:2147‑55.
- 13. Kim WT, Kuo MF, Mishra OP, Delivoria‑Papadopoulos M. Distribution and expression of the subunits of N‑methyl‑D‑aspartate (NMDA) receptors; NR1, NR2A and NR2B in hypoxic newborn piglet brains. Brain Res 1998;799:49‑54.
- 14. Boyce S, Wyatt A, Webb JK, O'Donnell R, Mason G, Rigby M, *et al*. Selective NMDA NR2B antagonists induce antinociception without motor dysfunction: Correlation with restricted localisation of NR2B subunit in dorsal horn. Neuropharmacology 1999;38:611-23.
- 15. Choi DW, Rothman SM. The role of glutamate neurotoxicity in hypoxic‑ischemic neuronal death.Annu Rev Neurosci 1990;13:171‑82.
- 16. Liu Y, Wong TP, Aarts M, Rooyakkers A, Liu L, Lai TW, *et al*. NMDA receptor subunits have differential roles in mediating excitotoxic neuronal death both *in vitro* and *in vivo*. J Neurosci 2007;27:2846‑57.
- 17. Kantos HA, Povlishok JT. Oxygen radicals in brain injury. Cent Nerv Sys Trauma 1986;3:257‑63.
- 18. Braugler JM, Hall ED. Central nervous system trauma and stroke. Biochemical concentrations for oxygen radical formation and lipid peroxidation. Free Rad Biol Med 1989;6:289‑301.
- 19. Lewen A, Matz P, Chan PH. Free radical pathways in CNS injury. Neurotrauma 2000;17:871‑90.
- 20. Dringen R. Metabolism and functions of glutathione in brain. Prog Neurobiol 2000;62:649‑71.
- 21. Chan PH, Kawase M, Murakami K, Chen SF, Li Y, Calagui B, *et al*. Overexpression of SOD1 in transgenic rats protects vulnerable neurons against ischemic damage after global cerebral ischemia and reperfusion. J Neurosci 1998;18:8292‑9.
- 22. Mikawa S, Kinouchi H, Kamii H, Gobbel GT, Chen SF, Carlson E, *et al*. Attenuation of acute and chronic damage following traumatic brain injury in copper, zinc‑superoxide dismutase transgenic mice. J Neurosurg 1996;85:885‑91.
- 23. Fan P, Yamauchi T, Noble LJ, Ferriero DM. Age-dependent differences in glutathione peroxidase activity after traumatic brain injury. J Neurotrauma 2003;20:437‑45.
- 24. Tyurin VA, Tyurina YY, Borisenko GG, Sokolova TV, Ritov VB, Quinn PJ, *et al*. Oxidative stress following traumatic brain injury in rats: Quantitation of biomarkers and detection of free radical intermediates. J Neurochem 2000;7:2178‑89.
- 25. Shahib MN, Syamsunarno MR, Faried A, Yuliana D, Anggraeni D, Yuniarti L, *et al*. The effect of glycine max extract diets on changes in NR2B gene expression, cognitive vitality and neurotoxicity in high concentrate consumption. Kitakanto Med J 2010;60:41-7.
- 26. Faried A, Kimura H, Faried LS, Usman N, Miyazaki T, Kato H, *et al*. Expression of carbohydrate antigens in human esophageal squamous cell carcinoma: Prognostic application and its diagnostic implication. Ann Surg Oncol 2006;14:960-7.
- 27. Feuerstein GZ, Wang X, Barone FC. Inflammatory gene expression in cerebral ischemia and trauma. Potential new therapeutic targets. Ann N Y Acad Sci 1997;825:179‑93.
- 28. Shohami E, Beit‑Yannai E, Horowitz M, Kohen R. Oxidative stress in closed-head injury: Brain antioxidant capacity as an indicator of functional outcome. J Cereb Blood Flow Metab 1997;17:1007-19.
- 29. Rodriguez C, Mayo JC, Sainz RM, Antolín I, Herrera F, Martín V, *et al*. Regulation of antioxidant enzyme: A significant role for melatonin. J Pineal Res 2004;36:1‑9.
- 30. Wang H, Cheng E, Brooke S, Chang P, Sapolsky R. Over-expression of antioxidant enzymes protects cultured hippocampal and cortical neurons from necrotic insults. J Neurochem 2003;87:1527‑34.
- 31. Mayer ML, Westbrook GL. Permeation and block of N‑methyl‑D‑aspartic acid receptor channels by divalent cations in mouse cultured central neurones. J Physiol 1987;394:501-27.
- 32. Meldrum B, Garthwaite J. Excitatory amino acid neurotoxicity and neurodegenerative disease. Trends Pharmacol Sci 1990;11:379‑87.
- 33. Ascher P, Nowak L. The role of divalent cations in the NMDA response of mouse central neurons in culture. J Physiol 1988;399:247‑66.
- 34. Ogura A, Miyamoto M, Kudo Y. Neural death *in vitro*: Parallelism between survivability of hyppocampal neurons and sustained elevation of cytosolic Ca^{2+} after exposure to glutamate receptor agonist. Exp Brain Res 1988;73:447‑58.
- 35. Verma A. Opportunities for neuroprotection in traumatic brain injury. J Head Trauma Rehabil 2000;15:1149‑61.
- 36. Murthy TV, Bhatia P, Sandhu K, Prabhakar T, Gogna RL. Secondary brain injury: Prevention and intensive care management. Indian J Neurotrauma 2005;2:7‑12.
- 37. Bigford GE, Alonso OF, Dietrich D, Keane RW. A novel protein complex in membrane Rafts lingking the NR2B glutamate receptor and autophagy is disrupted following traumatic brain injury. J Neurotrauma 2009;26:703‑20.
- 38. Murphy AN, Fiskum G, Beal MF. Mitochondria in neurodegeneration: Bioenergic function in cell life and death. J Cereb Blood Flow Metab 1999;19:231‑45.

How to cite this article: Arifin MZ, Faried A, Shahib MN, Wiriadisastra K, Bisri T. Inhibition of activated *NR2B* gene- and caspase-3 protein-expression by glutathione following traumatic brain injury in a rat model. Asian J Neurosurg 2011;6:72-7.

Source of Support: Universitas Padjadjaran, **Conflict of Interest:** None declared.